摘要
目的探究冠心病慢性心力衰竭发病因素,并观察盐酸曲美他嗪片对冠心病慢性心力衰竭的临床疗效。方法本探究对象为2015年2月~2017年2月于我院治疗的160例冠心病患者,其中80例为冠心病慢性心力衰竭患者(CHF组),80例未出现慢性心力衰竭(非CHF组),调查两组患者性别、年龄、病程及合并症等疾病情况,探究冠心病CHF的影响因素。对CHF组再次分组,随机均分两组,各40例,分别做观察组与对照组,对照组采用常规治疗,观察组在此基础上加用盐酸曲美他嗪片,比较临床疗效以及治疗前后心脏功能。结果冠心病CHF发病危险因素有病程、年龄、高血压、吸烟史、饮酒史、心律失常、糖尿病,有统计学意义(P<0.05);logistic回归性分析结果独立危险因素有心律失常(OR=1.546,95%CI为1.123~4.678)、高血压(OR=1.321,95%CI为1.121~5.654)、吸烟史(OR=1.213,95%CI为1.143~4.845);观察组治疗总有效率为87.50%,显著高于对照组(75.00%),有统计学意义(P<0.05);两组治疗前后左心室舒张末内径(LVEDV)、6min步行距离(6MWT)、左心室射血分数(LVEF)均有显著性差异,且治疗后观察组显著优于对照组,有统计学意义(P<0.05)。结论病程、年龄、高血压、吸烟史、饮酒史、心律失常、糖尿病均是引发冠心病慢性心力衰竭的危险因素,在常规用药基础上加用盐酸曲美他嗪片能够提升治疗效果,在改善心脏功能方面效果更佳。
Objective To investigate the pathogenic factors of coronary heart disease patients complicated by chronic heart failure（CHF） and the clinical effect of trimetazidine hydrochloride tablets. Methods A total of 160 patients with coronary heart disease who were treated in our hospital from February 2015 to February 2017 were enrolled,among whom 80 patients had coronary heart disease complicated by chronic heart failure（CHF group） and 80 had no CHF（non-CHF group）. The two groups were analyzed in terms of sex, age, course of disease, and comorbidities to investigate the influencing factors for coronary heart disease complicated by CHF. The CHF group was further divided into observation group and control group, with 40 patients in each group. The patients in the control group were given conventional treatment, and those in the observation group were given trimetazidine hydrochloride tablets in addition to the conventional treatment in the control group. The two groups were compared in terms of clinical outcome and cardiac function before and after treatment. Results Course of disease, age, hypertension, smoking history, drinking history,arrhythmia, and diabetes were risk factors for coronary heart disease complicated by CHF（P〈0.05）. The logistic regression analysis showed that arrhythmia（odds ratio [OR] =1.546, 95% confidence interval [CI] 1.123-4.678）,hypertension（OR=1.321, 95%CI 1.121-5.654）, and smoking history（OR=1.213, 95%CI 1.143-4.845） were independent risk factors. The observation group had a significantly higher overall response rate than the control group（87.50% vs75.00%, P〈0.05）. Both groups had significant changes in left ventricular end-diastolic diameter, six-minute walk distance, and left ventricular ejection fraction after treatment, and the observation group had significantly better results than the control group（P〈0.05）. Conclusion Course of disease, age, hypertension, smoking history, drinking history,arrhythmia, and diabetes are risk factors for coronary heart disease complicated by CHF. Routine medication combined with trimetazidine dihydrochloride tablets can improve the therapeutic outcome and has a good effect in improving cardiac function.
作者
敖先伟
AO Xian-wei(The Second People＇s Hospital of Jingzhou, Jingzhou 434000, Chin)
出处
《心血管病防治知识（学术版）》
2017年第9期47-50,共4页
Prevention and Treatment of Cardiovascular Disease
关键词
盐酸曲美他嗪片
冠心病慢性心力衰竭
发病因素
Trimetazidine dihydrochloride tablet
Coronary heart disease complicated by chronic heart failure
Pathogenic factor
